Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Gross Margin (2020 - 2025)

Harmony Biosciences Holdings' Gross Margin history spans 6 years, with the latest figure at 71.88% for Q4 2025.

  • For Q4 2025, Gross Margin fell 108.0% year-over-year to 71.88%; the TTM value through Dec 2025 reached 77.16%, down 90.0%, while the annual FY2025 figure was 77.16%, 90.0% down from the prior year.
  • Gross Margin for Q4 2025 was 71.88% at Harmony Biosciences Holdings, down from 75.09% in the prior quarter.
  • Across five years, Gross Margin topped out at 82.81% in Q2 2021 and bottomed at 71.88% in Q4 2025.
  • The 5-year median for Gross Margin is 81.17% (2023), against an average of 79.73%.
  • The largest annual shift saw Gross Margin plummeted -467bps in 2023 before it surged 46bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 80.47% in 2021, then dropped by -2bps to 79.05% in 2022, then fell by -6bps to 74.38% in 2023, then dropped by -2bps to 72.97% in 2024, then fell by -1bps to 71.88% in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Gross Margin are 71.88% (Q4 2025), 75.09% (Q3 2025), and 80.97% (Q2 2025).